Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
PDS Biotechnology Corporation is a biotechnology business based in the US. PDS Biotechnology Corporation shares (PDSB) are listed on the NASDAQ and all prices are listed in US Dollars. PDS Biotechnology Corporation employs 13 staff and has a market cap (total outstanding shares value) of USD$104.9 million.
|52-week range||USD$0.6153 - USD$6.35|
|50-day moving average||USD$3.6715|
|200-day moving average||USD$2.6594|
|Wall St. target price||USD$6.62|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.117|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing PDS Biotechnology Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PDS Biotechnology Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PDS Biotechnology Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, PDS Biotechnology Corporation shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$0|
|Return on assets TTM||-32.15%|
|Return on equity TTM||-64.36%|
|Market capitalisation||USD$104.9 million|
TTM: trailing 12 months
There are currently 458,910 PDS Biotechnology Corporation shares held short by investors – that's known as PDS Biotechnology Corporation's "short interest". This figure is 19.2% up from 385,048 last month.
There are a few different ways that this level of interest in shorting PDS Biotechnology Corporation shares can be evaluated.
PDS Biotechnology Corporation's "short interest ratio" (SIR) is the quantity of PDS Biotechnology Corporation shares currently shorted divided by the average quantity of PDS Biotechnology Corporation shares traded daily (recently around 424916.66666667). PDS Biotechnology Corporation's SIR currently stands at 1.08. In other words for every 100,000 PDS Biotechnology Corporation shares traded daily on the market, roughly 1080 shares are currently held short.
However PDS Biotechnology Corporation's short interest can also be evaluated against the total number of PDS Biotechnology Corporation shares, or, against the total number of tradable PDS Biotechnology Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PDS Biotechnology Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 PDS Biotechnology Corporation shares in existence, roughly 20 shares are currently held short) or 0.0241% of the tradable shares (for every 100,000 tradable PDS Biotechnology Corporation shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PDS Biotechnology Corporation.
Find out more about how you can short PDS Biotechnology Corporation stock.
We're not expecting PDS Biotechnology Corporation to pay a dividend over the next 12 months.
PDS Biotechnology Corporation's shares were split on a 1:20 basis on 18 March 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your PDS Biotechnology Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for PDS Biotechnology Corporation shares which in turn could have impacted PDS Biotechnology Corporation's share price.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer; and an agreement with Farmacore Biotechnology for the development of Versamune-based vaccine to prevent COVID-19 infection. The company is based in Princeton, New Jersey.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.